KRAS and colorectal cancer: Due to this, downstream signaling in G13D-mutated cells is extremely RTK-dependent, possibly explaining why KRASG13D-mutated colorectal cancers are sensitive to EGFR-TKIs while other KRAS-mutated colorectal tumors are refractory to EGFR-TKI treatment [145].